Huge Disappointment Has it crossed anyone's mind that if this technology is what the company says it is, it should be attracting more interest in the market and by competitors?
Why wouldn't DermTech make a buyout offer for MEDX if they can analyze skin lesions more cheaply and effectively? Could one or more of their patents be problematic? I would love to know why DermTech has shown what seems to be zero interest in acquiring this company.
I am long this company's shares and want them to be successful but the caginess of management is worrisome and the lack of interest by DermTech is not helping. Hopefully this stock simply hasn't appeared on their radar. If I were DermTech management, I'd take a good, hard look at Medx. In the meantime, I'm taking an unwelcome beating. The only thing that kept me from going in more heavily was the lack of US volume.
I'd appreciate any feedback on my points. GLTA longs.